Trials / Completed
CompletedNCT00736151
Phase II Dose Titration Study in Patients With Neuropathic Pain
A Phase II, Multicentre, Pilot, Randomised, Double Blind Placebo Controlled Dose Titration Study to Evaluate the Safety, Maximum Tolerated Dose and Preliminary Evidence of Efficacy of Orally Administered Ralfinamide at Four Doses (80, 160, 240 and 320 mg/Day) in Patients With Neuropathic Pain
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 272 (actual)
- Sponsor
- Newron Pharmaceuticals SPA · Industry
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to examine the effects of various increasing doses of Ralfinamide in patients with neuropathic pain.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ralfinamide | Oral tablets administered at rising doses of 80 - 320 mg/day |
Timeline
- Start date
- 2004-05-01
- Primary completion
- 2007-04-01
- First posted
- 2008-08-15
- Last updated
- 2009-08-07
Locations
47 sites across 6 countries: Austria, Czechia, India, Italy, Poland, United Kingdom
Source: ClinicalTrials.gov record NCT00736151. Inclusion in this directory is not an endorsement.